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Abstract
Background Aspirin and other non-steroidal anti-inﬂammatory drugs (NSAIDs) may have a preventive effect against
prostate cancer. However, evidence is limited and still controversial, especially considering non-aspirin non-steroidal anti-
inﬂammatory drugs (NSAIDs).
Methods Swedish nationwide population-based cohort study including all long-term (≥180 days) adult male users of aspirin
(n= 419,931) or NSAIDs (n= 223,437) followed from the ﬁrst dispense date until the ﬁrst cancer diagnosis, death or 31
December 2012, whichever occurred ﬁrst. The risk of prostate cancer was measured as standardized incidence ratios (SIR)
and 95% conﬁdence intervals (CI), assessing duration of use, age and concomitant statins intake, comparing to the general
male background population of the same age in Sweden.
Results The overall SIR suggests that maintenance use of aspirin decreases the risk of prostate cancer (SIR= 0.87, 95% CI
0.85–0.88), in particular if used ≥5 years (SIR= 0.31, 95% CI 0.30–0.32). The overall risk was decreased (SIR= 0.87, 95%
CI 0.85–0.90) among other NSAIDs users, and again in particular among longer-term users (≥3 years) with SIR= 0.58 (95%
CI 0.53–0.63). When statins users were excluded from all aspirin users, there was no remaining association with prostate
cancer (SIR= 0.99, 95% CI 0.96–1.02), only if taken ≥5 years (SIR= 0.31, 95% CI 0.29–0.34). For non-aspirin NSAIDs
users, the protective effect remained after exclusion of statins users (SIR= 0.92, 95% CI 0.88–0.95).
Conclusions This population-based cohort study provides evidence for a protective effect of aspirin and other NSAIDs
against prostate cancer, in particular for longer durations of use, yet concomitant use of statins strongly inﬂuences the risk
among aspirin users.
Key points
Question: Can aspirin or other non-steroidal anti-inﬂam-
matory drugs (NSAIDs) decrease the risk of prostate cancer?
Findings: this Swedish population based cohort study
indicates a protective effect after long term maintenance use
of aspirin or other NSAIDs against prostate cancer.
Meaning: long-term intake of aspirin or other NSAIDs is
probably useful in the prevention of prostate cancer.
Introduction
Chronic inﬂammation contributes to about 20% of all
human cancers in adults [1, 2]. For prostate cancer speci-
ﬁcally, there is evidence that chronic or recurrent inﬂam-
mation plays an important role in prostate cancer initiation,
development, progression, and metastasis [3]. Biopsies in
several carcinogenic and non-carcinogenic prostate diseases
show signs of inﬂammation, including prostatitis, benign
prostatic hyperplasia (BPH), prostate cancer “risk lesions”
(proliferative inﬂammatory atrophy (PIA), prostatic intrae-
pithelial neoplasia (PIN)), and prostate cancer [4–6].
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are a
family of drugs which can reduce pain and fever by inhi-
biting inﬂammation. Most NSAIDs can reversibly inhibit
cyclooxygenase enzyme activity on both COX-1 and
COX-2 receptors, yet some are selective on COX-2 [7].
Cyclooxygenase, also named prostaglandin-endoperoxide
synthase (PTGS), is an enzyme family responsible for
prostanoids formation. COX-1 is constitutively expressed in
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many tissues [8]. COX-2 expressed more speciﬁc in
inﬂammation and can be induced by extracellular or intra-
cellular stimuli and the induction is transient [9–11]. In
prostate cancer, COX-2 expresses speciﬁcally in prostate
inﬂammatory cells, especially in PIA lesions [5, 12].
Aspirin is a non-selective cyclooxygenase inhibitor, which
therefore irreversibly inhibits both COX-1 and COX-2 iso-
enzymes [13]. The potential cancer-preventive effect of
aspirin is increasingly investigated with ongoing clinical
trials aiming to prevent colorectal cancer [14]. Yet, for other
cancer types, the effect on carcinogenesis is less clear based
on observational studies.
Recent original publications and meta-analysis which
included 18 case-control and 13 cohort studies tried to assess
the association between aspirin and non-aspirin NSAIDs [15,
16]. Results suggested that aspirin could decrease the risk of
prostate cancer, especially after long-term use (≥4 years). In
terms of non-aspirin NSAIDs, this meta-analysis found no
protective effects against prostate cancer and authors claimed
that the results were less consistent and need further inves-
tigation. The major problems of these observational studies
were (1) Insufﬁcient power because of limited sample sizes
and follow-up time, in particular for non-aspirin NSAIDs
which are less commonly used than aspirin; (2) different
deﬁnitions of exposure which often based on e.g., ques-
tionnaires, interviews or medical notes, with a high risk of
recall bias and incomplete/incorrect information on exposure
in particular dose and duration. Statins are also considered
promising chemo-preventive agents commonly prescribed in
particular among aspirin users, although there is currently
insufﬁcient evidence supporting a protective effect against
prostate cancer [17–20]. To our knowledge, no previous
studies investigated the combined effect of NSAIDs and
statins on the risk of prostate cancer.
We assume that the risk of prostate cancer is decreased in
adults exposed to maintenance use of aspirin and other
NSAIDs comparing to the background population. The aim of
our study was therefore to evaluate the potential chemo-
preventive effect of maintenance use of aspirin or other
NSAIDs against prostate cancer in a Swedish population-
based cohort study taking into account concomitant statins use.
Methods
Design
This nationwide population-based cohort study was
designed to evaluate prostate cancer risk in adult (≥18
years) male aspirin users (N= 419,931) and non-aspirin
NSAIDs users (N= 223,437) compared to the general
Swedish male background population of the same age. All
individuals with at least 180 days of aspirin or other
NSAIDs between 1 July 2005 (the start date of the Swedish
Prescribed Drug Registry) and 31 December 2012, were
selected from the Swedish Prescribed Drug Registry. Indi-
viduals were followed up from the ﬁrst dispense date until
the ﬁrst cancer diagnosis, death or 31 December 2012,
whichever occurred ﬁrst. Individuals who were diagnosed
with any cancer (except non-melanoma skin cancer) before
or within 1 year after the ﬁrst prescription were excluded, as
well as those who use both ≥180-day aspirin and ≥180-day
of other NSAIDs.
Data collection
This study is approved by the Regional Ethical Review
Board (2014/1291-31/4) and informed consent was not
required. The 10-digit personal identity number was used to
link all individuals with the Swedish Cancer Registry and
Swedish Causes of Death Registry. The completeness of
prostate cancer diagnoses in the Swedish Cancer Registry is
more than 95% when compared to records of death certi-
ﬁcates and it was used to identify cancer cases among the
exposed cohort and background population [21]. Person
years for the background population are obtained from
Statistics Sweden (SCB), and cancer occurrence from the
Cancer Registry.
Exposures
Maintenance use of aspirin or NSAIDs was deﬁned as at
least 180 days during the study period before any cancer
diagnosis. This cumulative exposure was based on the
deﬁned daily dosage (DDD) per prescribed package, which
is an estimation of the number of days of use for the stan-
dard indication for an average individual (as deﬁned by the
World Health Organization). In Sweden, people can also
buy high-dose aspirin and some of the other NSAIDs over-
the-counter without prescription, but prescribed drugs are
less expensive, and therefore expected to be the major
source of NSAID intake among chronic users [22]. Expo-
sure data were collected by corresponding anatomical
therapeutic chemical classiﬁcation codes (ATC): Aspirin
(B01AC06; N02BA) and non-aspirin NSAIDs (M01A).
Individuals with ≥180 days of use of both aspirin and non-
aspirin NSAIDs were excluded.
Outcomes
The outcome was a ﬁrst diagnosis of prostate cancer
recorded in the Swedish Cancer Registry using the Inter-
national Classiﬁcation of Diseases (ICD) 10th codes (C61.9)
during the study period. Prostatic adenocarcinoma (diag-
nostic code is 096) was the single most common histolo-
gical type of prostate cancer in this cohort (98.7%), and was
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therefore not analyzed separately. Cancer which occurred
within 1 year after the ﬁrst prescription was excluded.
Statistical analyzes
Standardized incidence ratios (SIRs) and 95% conﬁdence
intervals (CI) were calculated by comparing aspirin users
and other NSAIDs users with the general Swedish back-
ground population of the corresponding age (18–49, 50–59,
60–69, 70–79, or ≥80 years) and calendar period
(2005–2006, 2007–2009, and 2010–2012). Expected inci-
dence rates were calculated based on data from the Swedish
cancer registry and general Swedish population (SCB).
Variance between groups were similar based on large
sample size study design. Subgroup analyzes were con-
ducted to assess the effected of duration of use (categorized
as <1 year, 1–3 years, 3–5 years, and >5 years for aspirin,
and <1 year, 1–3 years, and >3 years for NSAIDs), and
concomitant statins use (deﬁned as ≥180 days during the
study period). To assess the interaction between NSAIDs
use and statins, multivariable Poisson regression model
were used adjusting for age, for aspirin users and for non-
aspirin NSAIDs users separately, and expressing the risk of
prostate cancer as incidence rate ratios (IRR) and 95% CI
for statins users compared to non-statins users.
Code availability
The data were analyzed by StataIC 13. The code is available
upon request.
Results
Participants
In this cohort, 419,931 men (65.3%) were considered
aspirin maintenance users, and 223,437 (34.7%) non-aspirin
NSAIDs users (Table 1). Non-aspirin NSAIDs were
younger than aspirin users (respectively, 43.2% and 6.3%
younger than 50-years). Concomitant maintenance use of
statins was found in 62.9% of the aspirin users and 14.7%
of the non-aspirin NSAIDs users.
Aspirin use
Among aspirin users, 11,291 (2.7%) developed prostate cancer
(Table 1). The overall SIR indicated a protective effect of
aspirin on prostate cancer (SIR= 0.87, 95% CI 0.85–0.88)
(Table 2). This reduced risk was seen among all age groups
except for those younger than 50 years (showing no associa-
tion) (Table 2). When the duration of use was taken into
account, the protective effect was only seen among long-term
users of aspirin (more than 5 years) with SIR= 0.31 (95% CI
0.30–0.32) (Table 3). After exclusion of aspirin users who also
used statins, no association with prostate cancer remained (SIR
= 0.99, 95% CI 0.96–1.02), except for the long-term users
(SIR= 0.31, 95% CI 0.29–0.34) (Tables 2, 3). When assessing
concomitant statins use among aspirin users by means of
Poisson regression adjusting for age, statins use was associated
with a 22% reduced risk of prostate cancer (IRR= 0.78, 95%
CI 0.75–0.81) compared to non-statins users (Table 4).
Non-aspirin NSAIDs use
Among all non-aspirin NSAIDs users, 3578 (1.6%) people
developed prostate cancer (Table 1). An overall SIR (0.87,
95% CI 0.85–0.90) was found showing a preventive effect
of NSAIDs against prostate cancer. Yet, the association was
only signiﬁcantly protective among those aged 50–59 and
60–69 (Table 2). When assessing the duration of use, the
preventive effect was seen from a use of 1 year or more,
with the strongest preventive effect among the longest-term
users (more than 3 years), with SIR= 0.58 (95% CI
0.53–0.63) (Table 3). After exclusion of those also using
statins, the preventive effect remained, although less pro-
nounced (SIR= 0.92, 95% CI 0.88–0.95) (Tables 2, 3).
Among other NSAIDs users, concomitant statins use
showed a 20% reduced risk of prostate cancer (IRR= 0.80,
95% CI 0.73, 0.87) compared to non-statins users (Table 4).
Discussion
This study suggested an overall decreased risk of prostate
cancer among non-aspirin NSAIDs users, in particular when
Table 1 Descriptive characteristics of aspirin users and non-aspirin
non-steroidal anti-inﬂammatory drugs (NSAIDs) users
Aspirin Non-aspirin NSAIDs
Number (%) Number (%)
Total 419,931 223,437
Age
18–49 years 26,604 (6.3) 96,598 (43.2)
50–59 years 73,732 (17.6) 61,045 (27.3)
60–69 years 126,030 (30.0) 44,296 (19.8)
70–79 years 111,182 (26.5) 16,578 (7.4)
≥80 years 82,383 (19.6) 4920 (2.2)
Statins users
Yes 264,275 (62.9) 32,839 (14.7)
No 155,656 (37.1) 190,598 (85.3)
Prostate cancer
All 11,291 (2.7) 3578 (1.6)
Adenocarcinoma 11,128 (2.6) 3562 (1.6)
Follow-up (person-years)
Total 2,053,932 1,305,848
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Table 2 The risk of prostate
cancer among maintenance users
of aspirin and NSAIDs stratiﬁed
by statins-use, measured by
standardized incidence ratios
(SIRs)
Aspirin (N= 419,931) Non-aspirin NSAIDs (N= 223,437)
Prostate
cancer
SIRs (95% CI) P-value Prostate
cancer
SIRs (95% CI) P-value
All 11,291 0.87 (0.85, 0.88) <0.01 3578 0.87 (0.85, 0.90) <0.01
18–49 years 6 1.65 (0.60, 3.60) 0.33 31 1.56 (1.06, 2.21) 0.02
50–59 years 392 0.74 (0.67, 0.82) <0.01 503 0.77 (0.70, 0.84) <0.01
60–69 years 3328 0.83 (0.80, 0.86) <0.01 1677 0.83 (0.79, 0.87) <0.01
70–79 years 4423 0.87 (0.84, 0.90) <0.01 1043 0.95 (0.90, 1.01) 0.12
≥80 years 3142 0.93 (0.90, 0.97) <0.01 324 1.10 (0.99, 1.23) 0.08
Statins user
subgroup
(N= 264,275) (N= 32,839)
All 6982 0.80 (0.79, 0.82) <0.01 655 0.72 (0.67, 0.78) <0.01
18–49 years 4 1.63 (0.44, 4.17) 0.51 2 1.68 (0.19, 6.05) 0.78
50–59 years 265 0.65 (0.58, 0.74) <0.01 59 0.56 (0.43, 0.72) <0.01
60–69 years 2329 0.75 (0.72, 0.78) <0.01 313 0.66 (0.59, 0.73) <0.01
70–79 years 2882 0.79 (0.77, 0.82) <0.01 237 0.86 (0.75, 0.97) 0.02
≥80 years 1502 0.99 (0.94, 1.04) 0.63 44 0.89 (0.65, 1.19) 0.47
Non-statins user
subgroup
(N= 155,656) (N= 190,598)
All 4309 0.99 (0.96–1.02) 0.63 2923 0.92 (0.88–0.95) <0.01
18–49 years 2 1.71 (0.19–6.17) 0.76 29 1.55 (1.04–2.23) 0.02
50–59 years 127 1.03 (0.86–1.23) 0.77 444 0.81 (0.73–0.89) <0.01
60–69 years 999 1.10 (1.03–1.17) <0.01 1364 0.88 (0.83–0.92) <0.01
70–79 years 1541 1.06 (1.01–1.11) 0.03 806 0.99 (0.92–1.06) 0.69
≥80 years 1640 0.89 (0.84–0.93) <0.01 280 1.15 (1.02–1.29) 0.02
Table 3 Duration uses of
Aspirin and NSAIDs stratiﬁed
by statins use, measured by
standardized incidence ratios
(SIRs)
Aspirin (N= 419,931) Non-aspirin NSAIDs (N= 223,437)
Prostate
cancer
SIRs (95% CI) P-value Prostate
cancer
SIRs (95% CI) P-value
All 11,291 3578
0–1 years 533 1.06 (0.97, 1,15) 0.23 1574 1.00 (0.95, 1.05) 0.92
1–3 years 4372 2.65 (2.57, 2.73) <0.01 1531 0.90 (0.86, 0.95) <0.01
3–5 years 3764 1.61 (1.56, 1.66) <0.01
473 0.58 (0.53, 0.63) <0.01
>5 years 2622 0.31 (0.30, 0.32) <0.01
Statins user
subgroup
All 6982 655
0–1 years 214 0.93 (0.81, 1,07) 0.33 259 0.82 (0.72, 0.93) <0.01
1–3 years 2409 2.55 (2.45, 2.65) <0.01 292 0.75 (0.67, 0.84) <0.01
3–5 years 2545 1.63 (1.57, 1.69) <0.01
104 0.51 (0.42, 0.62) <0.01
>5 years 1814 0.31 (0.29, 0.32) <0.01
Non-statins user
subgroup
All 4309 2923
0–1 years 319 1.16 (1.03–1.29) 0.01 1315 1.04 (0.99–1.10) 0.14
1–3 years 1963 2.79 (2.67–2.92) <0.01 1239 0.95 (0.90–1.00) 0.06
3–5 years 1219 1.57 (1.49–1.67) <0.01
369 0.60 (0.54–0.66) <0.01
>5 years 808 0.31 (0.29–0.34) <0.01
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taken over a longer-period of time. Although aspirin
showed some protective effect against prostate cancer, this
association was clearly inﬂuenced by statins use—which is
taken concomitantly by 63% of the aspirin users.
The main strength of this study was the large sample size
introduced by population-based design which included all
Swedish adults during the study period. The nationwide
Swedish health registries are an accurate and valid data
source, in particular to deﬁne prescribed drug use—elim-
inating the risk of recall bias, and reducing the risk of
misclassiﬁcation of the exposure.
Nevertheless, some NSAIDs may have been bought
over-the-counter, in particular high-dose aspirin (for pain
relief) and some NSAIDs. Yet, since prescribed drugs are
available at a lower price, we expect that the majority of
NSAIDs use has been recorded, in particular among long-
term users. Unfortunately, we do not have information on
drug use before the initiation of the Prescribed Drug Reg-
istry (July 2005). One of the limitations of our study is that
our design only took into account confounding by age and
calendar period, and the interaction between aspirin/
NSAIDs and statins could not be measured based on the
design, because we standardized the incidence of prostate
cancer by using the total Swedish background population
for which only limited information was available. Since
aspirin and NSAIDs are commonly used drugs in Sweden,
this approach may have diluted our results.
Obesity is a known risk factor for prostate cancer, yet
body mass index is not registered in the nationwide Swedish
registries, and the diagnosis obesity is underreported; so this
could not be taken into account. Another risk factor that
cannot be taken into account either is diet, since men who
consume large amount of meat or high-fat products may
have an increased risk to develop prostate cancer. Sweden is
highly developed yet relatively small country considering
the number of inhabitants (~10 million) and the majority of
the population is of European decent with relatively limited
differences in socio-economic status, so we assume that
socio-economic and ethno-geographic risk factors have a
limited impact on the results. Confounding by indication
may, however, be a problem, in particular for aspirin use,
since aspirin use may be administered for thrombotic events
related to cancer, although a 6 month duration of aspirin use
before any cancer diagnosis was used to deﬁne maintenance
use [23]. Unfortunately, no data on prescribed drug use
before July 2005 could be collected since The Swedish
Prescribed Drug Registry started from 1 July 2005. We
assessed only the estimated duration of use by average
DDDs per package instead of accurate daily dose and
duration, which may have resulted in over or under-
estimation of the real duration of use.
Overall, the current project showed that 2.6% of aspirin
users developed prostate cancer, and 1.6% among other
NSAIDs users. A higher proportion of aspirin users devel-
oped prostate cancer compared to the other NSAIDs users,
yet this was also heavily inﬂuenced by the different age
distribution where aspirin users were markedly older.
The effect of statins use is controversial in current pub-
lications and there is no conclusion if long term use of
statins could decrease prostate cancer incidence [24]. In our
study when statins users were removed from the analyzes,
the protective effect of aspirin and non-aspirin NSAIDs was
clearly less pronounced which suggests a not negligible
interaction with statins especially among aspirin users who
commonly use both drugs. The subgroup analysis com-
paring the effects of aspirin use among those who do and do
not use statins are of particular interest, since both drugs are
often used in parallel (i.e., individuals with a cardiovascular
risk proﬁle). Previous studies did not assess concomitant
use, yet our results indicate that the shown preventive effect
of aspirin may be largely attributed to the statins instead.
To better understand the role of aspirin and NSAIDs use
in the development of prostate cancer, it may be useful to
assess previous drug exposure in cohorts of pre-malignant
or inﬂammatory prostate diseases for whom biopsy material
is available, so local inﬂammatory patterns could be
explored further. This may help to identify high-risk
populations which could beneﬁt most from chronic
aspirin/NSAIDs intake in the prevention (or progression) of
prostate cancer.
Conclusions
This Swedish population-based cohort study indicated a
protective effect of aspirin and other NSAIDs against
prostate cancer after long-term maintenance use, yet the
combined effect of statins use should not be neglected.
Table 4 Incidence rate (IR) and
incidence rate ration (IRR) of
aspirin and non-aspirin NSAIDs
against prostate cancer,
adjusting for age
Statins Events IR (per 1000) IRR P-value
Aspirin and Non-aspirin NSAIDs group No 7232 3.99 1.0 —
Yes 7637 4.54 0.81 (0.78, 0.83) <0.01
Aspirin group No 4309 6.57 1.0 —
Yes 6982 4.99 0.78 (0.75, 0.81) <0.01
Non-aspirin NSAIDs group No 2923 2.64 1.0 —
Yes 655 3.30 0.80 (0.73, 0.87) <0.01
Maintenance and use of aspirin or NSAIDs
Acknowledgments SFO epidemiology (Karolinska Institutet).
Authors’ contributions Literature search: Y.M.+N.B.; design of the
study: Y.M.+N.B.; data collection and preparation for analyzes: N.B.;
data analysis: Y.M.+N.B.; data interpretation: Y.M.+N.B.; writing of
ﬁrst draft: Y.M., revised and approved by all authors.
Compliance with ethical standards
Competing interests The authors declare that they have no competing
interests.
References
1. Ames BN, Gold LS, Willett WC. The causes and prevention of
cancer. Proc Natl Acad Sci USA. 1995;92:5258–65.
2. Coussens LM, Werb Z. Inﬂammation and cancer. Nature.
2002;420:860–7.
3. Stark T, Livas L, Kyprianou N. Inﬂammation in prostate cancer
progression and therapeutic targeting. Transl Androl Urol.
2015;4:455–63.
4. Schatteman PHF, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E.
Inﬂammation in prostate biopsies of men without prostatic
malignancy or clinical prostatitis - Correlation with total serum
PSA and PSA density. Eur Urol. 2000;37:404–12.
5. Gurel B, Lucia MS, Thompson IM, Goodman PJ, Tangen CM,
Kristal AR, et al. Chronic inﬂammation in benign prostate tissue is
associated with high-grade prostate cancer in the placebo arm of
the prostate cancer prevention trial. Cancer Epidem Biomar.
2014;23:847–56.
6. Fujita K, Hosomi M, Tanigawa G, Okumi M, Fushimi H,
Yamaguchi S. Prostatic inﬂammation detected in initial biopsy
specimens and urinary pyuria are predictors of negative repeat
prostate biopsy. J Urol. 2011;185:1722–7.
7. Knights KM, Mangoni AA, Miners JO. Deﬁning the COX inhi-
bitor selectivity of NSAIDs: implications for understanding toxi-
city. Expert Rev Clin Pharmacol. 2010;3:769–76.
8. Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D,
Mancini J, et al. Characterization of prostaglandin G/H synthase 1
and 2 in rat, dog, monkey, and human gastrointestinal tracts.
Gastroenterology. 1996;111:445–54.
9. Harris RC, Mckanna JA, Akai Y, Jacobson HR, Dubois RN,
Breyer MD. Cyclooxygenase-2 is associated with the macula
densa of rat-kidney and increases with salt restriction. J Clin
Invest. 1994;94:2504–10.
10. Hirst JJ, Teixeira FJ, Zakar T, Olson DM. Prostaglandin
endoperoxide-h synthase-1 and synthase-2 messenger-ribonucleic-
acid levels in human amnion with spontaneous labor onset. J Clin
Endocr Metab. 1995;80:517–23.
11. Hamasaki Y, Kitzler J, Hardman R, Nettesheim P, Eling TE.
Phorbol ester and epidermal growth-factor enhance the expression
of 2 inducible prostaglandin-h synthase genes in rat tracheal
epithelial-cells. Arch Biochem Biophys. 1993;304:226–34.
12. De Marzo AM, Platz EA, Sutcliffe S, Xu JF, Gronberg H, Drake
CG, et al. Inﬂammation in prostate carcinogenesis. Nat Rev
Cancer 2007;7:256–69.
13. Wennogle LP, Liang HB, Quintavalla JC, Bowen BR, Wasvary J,
Miller DB, et al. Comparison of recombinant cyclooxygenase-2 to
native isoforms - aspirin labeling of the active-site. FEBS Lett.
1995;371:315–20.
14. Patrignani P, Patrono C. Aspirin and cancer. J Am Coll Cardiol.
2016;68:967–76.
15. Liu Y, Chen J-Q, Xie L, Wang J, Li T, He Y, et al. Effect of
aspirin and other non-steroidal anti-inﬂammatory drugs on pros-
tate cancer incidence and mortality: a systematic review and meta-
analysis. BMC Med. 2014;12:55–69.
16. Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R,
Andriole GL, Freedland SJ. Aspirin, NSAIDs, and risk of prostate
cancer: results from the REDUCE study. Clin Cancer Res.
2015;21:756–62.
17. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of
prostate cancer: a metaanalysis of 6 randomized clinical trials and
13 observational studies. Int J Cancer. 2008;123:899–904.
18. Zhang Y, Zang T. Association between statin usage and prostate
cancer prevention: a reﬁned meta-analysis based on literature from
the years 2005-2010. Urol Int. 2013;90:259–62.
19. Tan P, Zhang C, Wei SY, Tang Z, Gao L, Yang L, et al. Effect of
statins type on incident prostate cancer risk: a meta-analysis and
systematic review. Asian J Androl. 2016; Epub ahead of print
(cited 2017 Jul 17). http://www.ajandrology.com/preprintarticle.
asp?id=190327.
20. Bansal D, Undela K, D’Cruz S, Schifano F, Statin use and risk of
prostate cancer: a meta-analysis of observational studies. PLoS
ONE.2012;7:e46691
21. Mattsson B, Wallgren A. Completeness of the Swedish Cancer
Register - Non-Notiﬁed Cancer Cases Recorded on Death Certi-
ﬁcates in 1978. Acta Radiol Oncol. 1984;23:305–13.
22. FASS (Farmacevtiska specialiteter i Sverige) [Internet]. 2015.
Available from: www.fass.se.
23. Kyriazi V, Theodoulou E. Assessing the risk and prognosis of
thrombotic complications in cancer patients. Arch Pathol Lab
Med. 2013;137:1286–95.
24. Allott EH, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria
R, Andriole GL, et al. Statin use, serum lipids, and prostate
inﬂammation in men with a negative prostate biopsy: results from
the REDUCE trial. Cancer Prev Res. 2017;10:319–25.
Y. Ma, N. Brusselaers
